in established glioblastoma (GBM) cell lines compared with surrounding normal brain, thereby presenting a potential target for GBMs. [4] [5] [6] However, there have been no reports that examine miR-7 levels in GBM stem cells (GSCs), a subpopulation of GBM cells with stem cell properties. In the current study, we have screened a cohort of patient-derived primary GSCs for their miR-7 expression and further established the role of a forced miR-7 expression in the growth of such GSC lines. Recent studies have shown that miR-7 inhibits tumor cell growth by simultaneously targeting phosphatidylinositol-3 kinase/Akt and Raf/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathways 7 and by regulating the insulin-like growth factor 1 receptor/Akt signaling pathway in tumor cells. 8 Although these studies indicate a strong role of miR-7 in targeting tumor cell proliferation pathways, there are no previous studies indicating the role of miR-7 in targeting the apoptotic pathways in tumor cells. In the current study, we explored the mechanism underlying the crosstalk between cell proliferation pathways targeted by miR-7 and the tumor necrosis factor apoptosis inducing ligand (TRAIL)/death receptor (DR) 4/5 mediated extrinsic apoptotic pathway in GBM cells and its potential therapeutic implications for GBM therapy.
The major impediment to efficient delivery of therapeutic molecules, including miRNAs, to the brain is the bloodbrain barrier (BBB), which prevents systemically delivered drugs from reaching brain tumor cells. 9, 10 In order to translate our in vitro findings into animal models and clinical application, it is essential to optimize methods to deliver both miR-7 and TRAIL to the tumor site. Owing to their low pathogenicity and immunogenicity compared with other viral vectors, as well as localized long-term gene expression, adeno-associated viruses (AAVs) have emerged as attractive gene transfer vehicles. Recently, AAVs have been shown to be effective in delivering therapeutic molecules to the brain. 11, 12 They have also been evaluated for clinical use and have been reported to be well tolerated in human subjects. 13 To overcome the limitations pertaining to the short half-life and the off-target toxicity of systemically delivered TRAIL, 14 we have previously established that mesenchymal stem cell (MSC)-delivered secretable (S)-TRAIL, a potent variant of TRAIL, is very effective in GBM eradication due to its on-site delivery and long-term expression compared with systemically administered purified TRAIL. [15] [16] [17] In this study, we evaluated the delivery and expression of miR-7 via AAV in vivo and explored the potential of the combined therapeutic strategy employing AAV-miR-7 and MSC-S-TRAIL to target cell proliferation and death pathways in GBM in vivo.
Materials and Methods

Cell Lines
Established human GBM lines (Gli36, U87, U251, LN319, LN229, and U373) were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and penicillin/streptomycin. GBM stem cells (GBM4, GBM8, GBM18, GBM23, GBM46, and GBM64) were cultured in Neurobasal medium supplemented with 3 mM L-glutamine, B27 (Invitrogen), 2 µg/mL heparin (Stem Cell Technologies), 20 ng/mL human epidermal growth factor, and 20 ng/mL human fibroblast growth factor 2 (R&D Systems) as described previously. 18 Human bone marrow-derived MSCs (Texas A&M University) were grown in Alpha-Minimum Essential Medium with 20% FBS, 3 mM L-glutamine (Invitrogen), and penicillin/streptomycin. LN229 and GBM4 cells were transduced with LV-Pico2-Fluc-mCherry (LN229-FmC; GBM4-FmC) at a multiplicity of infection (MOI) of 2 in medium containing protamine sulfate (2 µg/mL). LN229-FmC were transduced with reverse tetracycline-controlled transactivator (rtTA) and LV-Tetr-miR-7. MSCs were transduced with LV-S-TRAIL or LV-GFP (green fluorescent protein) at MOI of 5 in growth media containing protamine sulfate (2 µg/mL). Cells were visualized by fluorescence microscopy for mCherry expression 36 hours post transduction. GBM4 cells were infected with AAV-GFP (AGFP) or AAV-GFPmiR-7 (AGM7) at MOI of 2 in medium containing protamine sulfate (2 µg/mL) and were used for in vitro experiments. The concentrations of TRAIL in conditioned media of MSC-TRAIL were determined by enzyme-linked immunosorbent assay using a TRAIL Immunoassay Kit (Abcam) with recombinant human TRAIL expressed in Escherichia coli as a standard.
Nuclear Factor-KappaB p65 Transcription Factor Assay LN229 cells were treated with miR-7 alone or miR-7 + S-TRAIL in the presence or absence of 5 μM parthenolide with appropriate controls. The nuclear and cytosolic fractions of the cells were isolated 48 h post treatment using the NE-PER nuclear extraction kit (ThermoFisher Scientific). The nuclear factor-kappaB (NFkB) activity was then determined using the kit (Abcam). A specific double-stranded DNA sequence containing the NFkB response element was immobilized onto the bottom of wells of a 96-well plate. NFkB (p65) present in the nuclear extract was detected by addition of specific primary antibody directed against NFkB (p65). A secondary antibody conjugated to horseradish peroxidase was added to provide a sensitive colorimetric readout.
Intracranial GBM Cell Implantation and In Vivo Bioluminescence Imaging
To understand the effect of forced expression of miR-7, LN229-FmC-TetOn-miR-7 GBM cells (5 × 10 5 cells per mouse, n = 10) were stereotactically implanted into the brains (right striatum, 2.5 mm lateral from bregma and 2.5 mm deep) of severe combined immunodeficient (SCID) mice (6 wk of age). Mice were then administered doxycycline (Dox) (20 mg/kg) in drinking water to express miR-7-GFP 3 times per week for 2 weeks and followed for the GBM burden in real time by bioluminescence imaging (BLI) as described previously. 19 Mice were then harvested, brains were collected, and immunohistochemical analysis was performed as described below.
For assessment of AAV-miR-7, GBM4-FmC GSCs (5 × 10 5 cells per mouse, n = 24) were stereotactically implanted into the brains of SCID mice (right striatum, 2.5 mm lateral from bregma and 2.5 mm deep). Twenty-eight days post GBM4 injection, mice were randomly assigned to 2 groups,
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injected with AAV (AGFP or AGM7) (1 × 10 8 virions per mouse), and followed for the GBM burden in real time by BLI as described previously. 19 Mice (n = 3) were harvested on days 2, 5, 8, and 12, brains were collected, and immunohistochemical analysis was performed as described below.
To assess therapeutic benefit of the combination of miR-7 and S-TRAIL, LN229-FmC-TetOn-miR-7 GBM cells (5 × 10 5 cells per mouse, n = 28) were stereotactically implanted into the brains (right striatum, 2.5 mm lateral from bregma and 2.5 mm deep) of SCID mice 6 weeks of age. Mice were administered Dox (20 mg/kg) in drinking water to express copGFP-miR-7 three times per week. Mice were randomly assigned to 2 groups, implanted with MSCs (MSC-S-TRAIL or MSC-GFP) intratumorally, and followed for the GBM burden in real time by BLI as described previously. 19 Four days post treatment, mice (n = 3 in each group) were sacrificed for immunohistochemical analysis performed as described below.
To assess the therapeutic benefit of the combination of AAV-miR-7 and MSC-S-TRAIL, GBM4-FmC GSCs (5 × 10 5 cells per mouse, n = 28) were stereotactically implanted into brains of SCID mice (right striatum, 2.5 mm lateral from bregma and 2.5 mm deep). Twenty-eight days post tumor cell injections, mice were randomly assigned to 2 groups and injected with AAV (AGFP or AGM7) (1 × 10 8 virions per mouse). Three days later, mice were implanted with MSCs (MSC-S-TRAIL or MSC-GFP) intratumorally (1 × 10 6 cells per mouse) and followed for the GBM burden in real time by BLI as described previously, as well as followed for survival analysis. All in vivo procedures were approved by the Institutional Animal Care and Use Committee at Massachusetts General Hospital. Treatment groups were randomly assigned from the total number of mice that were included in the study, and the investigator was not blinded while administering the treatment.
Tissue Processing and Staining
Mice were perfused by pumping ice-cold 4% paraformaldehyde (PFA) directly into the heart, the brains were fixed in 4% PFA, and 25-micron frozen sections were obtained for hematoxylin and eosin (H&E) staining and immunohistochemistry. Sections were incubated for 1 hour in a blocking solution (0.3% bovine serum albumin, 8% goat serum, and 0.3% Triton X-100) at room temperature, followed by incubation at 4°C overnight with antiphospho-Akt (Cell Signaling Technologies). Sections were incubated in Alexa Fluor 647 goat anti-rabbit secondary antibody (Invitrogen) and visualized using a confocal microscope (Carl Zeiss). H&E staining was performed as described previously. 20 
Statistical Analysis
Pairwise comparisons were conducted using a 2-sample t-test with Bonferroni adjusted P-values for the cases of multiple pairwise tests. Data were expressed as mean ± SEM and differences were considered significant at P < 0.05. For survival analysis, Kaplan-Meier estimates and the log-rank test for the comparison of survival curves were conducted for all time to event outcomes.
Results
miR-7 upregulates DR5 Expression and Sensitizes Resistant GBM to DR-Ligand Induced Apoptosis
We screened a cohort of established GBM and primary GSCs for their miR-7 expression and show that the majority of the GBM cell lines have low expression of miR-7 compared with normal cells (Supplementary Figure S1A) . Next, we engineered a panel of established GBM and primary patient-derived GSCs to express miR-7. A significant reduction (P < 0.05) of cell viability was observed in 8 of 11 lines expressing miR-7 compared with controls ( Fig. 1A) . miR-7 activity reporter assay on established GBM cells expressing miR-7 confirmed the function of transcribed pre-miR-7 in GBM cells (Supplementary Figure S1B) . In order to correlate the activity of miR-7 to epidermal growth factor receptor (EGFR) levels, we screened a cohort of GBM cell lines for EGFR and EGFR variant (v)III levels by real time (RT)-PCR. Varying levels of EGFR expression were seen in the panel of lines tested, with one line showing EGFRvIII expression (Supplementary Figure S1C) . In order to assess the effect of miR-7 on the EGFRvIII-expressing GBM cell line, Gli36vIII, cell viability was evaluated 48 h post miR-7 treatment. A significant reduction in viability was observed post miR-7 treatment, suggesting that miR-7 elicits its effects in the EGFRvIII-expressing GBM cell lines (Supplementary Figure S1D) . Furthermore, immunoblot analysis revealed that miR-7 expression decreased EGFR protein levels and inhibited Akt phosphorylation in all 4 established GBM lines tested ( Supplementary Fig. S1E ).
To regulate miR-7 expression in GBM cells, we engineered a tetracycline (Tet) inducible miR-7 lentiviral vector, which bears both GFP and miR-7 cDNA under the control of the tetracycline responsive promoter (LV-TrmiR-7). LN229 GBM cells expressing firefly luciferase (Fluc)-mCherry (LN229-FmC) were further transduced with LV-rtTA and LV-Tr-miR-7 to create an imageable GBM line, LN229-FmC-Tr-miR-7 (Supplementary Figure S2) , in which miR-7 expression is Tet regulated. Dox induction resulted in a time-dependent increase in GFP expression (indicating expression of miR-7) in LN229-FmC-Tr-miR-7 GBM cells (Fig. 1B) . This was associated with the emergence of miR-7 activity and the inhibition of EGFR and the Akt pathway as revealed by miR-7 reporter assays (Fig. 1C) and western blot analysis (Fig. 1D) , respectively. Cell viability assays revealed a reduction in GBM cell viability with timedependent miR-7 induction (Fig. 1E) . These data reveal that expression of miR-7 results in reduced tumor cell proliferation in a broad spectrum of established GBM lines and primary GSCs independently of their EGFR or EGFRvIII expression.
Previous studies have shown that about 40% of GBMs have no or low expression levels of DR4/5 and do not respond to DR ligands such as TRAIL 21 (Supplementary Figure S3) . In order to understand the influence of miR-7 on the response of GBM cells to TRAIL-induced apoptosis, we utilized the LN229 GBM line that has significantly reduced expression of DR4/5 and does not respond to TRAIL. Western blot analysis performed on LN229-FmC-Tr-miR-7 GBM cells post-Dox induction of miR-7 showed upregulation of DR5 (Fig. 1F) and not DR4 (data not shown). This upregulation of DR5 primed TRAIL-resistant LN229 GBM cells to TRAIL-mediated apoptosis as demonstrated by cleavage of caspase-8 and poly(ADP-ribose) polymerase (PARP) that occurred as early as 2 hours after S-TRAIL addition and persisted (Fig. 1F, G) . RT-PCR analysis also revealed an increased level of DR5 mRNA in LN229-FmC-Tr-miR-7 GBM cells post-Dox induction of miR-7 (Supplementary Figure S4) , suggesting transcriptional regulation. In contrast, TRAIL treatment without miR-7 expression yielded no cleavage of caspase-8, with only transient induction of barely detectable PARP cleavage (Fig. 1F, G) . This was further confirmed by cell viability assays on LN229-FmC cells transduced with LV-miR-7 and subsequently treated with S-TRAIL conditioned medium that revealed a significant reduction in GBM cell survival (P < 0.01 compared with untreated group) (Fig. 1H) .
To understand the expression patterns of EGFR and DR5 in GBM patients, data from 166 patients were analyzed from The Cancer Genome Atlas and plotted for the transcript levels of EGFR and DR5. Both EGFR and DR5 mRNA were present in these patients; however, the levels of DR5 mRNA were significantly lower than EGFR mRNA levels ( Fig. 2A) . To assess the role of miR-7 upregulation of DR5, LN229 cells were transduced with short hairpin (sh)RNA targeting DR5 or control (scramble) and co-transduced with LV-miR-7 or control lentivirus and treated with S-TRAIL conditioned medium. Cell viability assays and western blot analysis revealed that shRNA silencing of DR5 abrogated the killing effect of the combination treatment with miR-7 and S-TRAIL (Fig. 2B) by preventing PARP cleavage in LN229 cells (Fig. 2C, D) .
Previous studies have shown that NFkB p65 transcription factor plays a vital role in upregulation of DR5 via histone deacetylase 1. 30 In order to investigate a role played 
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by NFkB in miR-7 mediated sensitization to TRAIL mediated apoptosis, we assessed changes in NFkB activity following treatment with miR-7 alone or in the presence of S-TRAIL with or without an NFkB inhibitor, parthenolide. A significant increase in the NFkB p65 transcription factor was seen in the nuclear fraction as well as the cytoplasmic fraction in the miR-7 alone and miR-7 + TRAIL treatment groups compared with controls (Fig. 2E) . These effects were not observed in the presence of the NFkB inhibitor, parthenolide. These results show miR-7-induced activation of the NFkB p65 transcription factor and suggest that NFkB p65 plays a role in miR-7 mediated DR5 upregulation that results in priming tumor cells to TRAIL-mediated apoptosis.
Induced Expression of miR-7 Co-operates with Stem Cell-Delivered S-TRAIL in Inhibiting Growth of GBM In Vitro and In Vivo
To test the effect of miR-7 on GBM growth in vivo, mice bearing established intracranial LN229-FmC-Tr-miR-7 were administered Dox 5 days post tumor implantation, and tumor volumes were followed by real time in vivo optical imaging (Fig. 3A) . Serial Fluc imaging revealed that induced miR-7 expression in tumor cells resulted in a significant attenuation (P < 0.5 compared with control) of tumor growth compared with controls. Immunofluorescence on brain sections post Dox treatment revealed the induction of miR-7 (as visualized by GFP expression) (Fig. 3B) , which resulted in a significant reduction in pAkt levels compared with control (Fig.  3C) . Although soluble recombinant human TRAIL protein has been used in a number of preclinical studies in different tumor types, its short half-life and delivery issues across the BBB limit its use in treating tumors in the brain. 22 We engineered human MSC to express a highly potent, secreted variant of TRAIL, S-TRAIL (Supplementary Figure S6A) . To test the combination effect of miR-7 and MSC-S-TRAIL on GBM in vitro, we first cultured LN229-FmC-Tr-miR-7 GBM cells in MSC-S-TRAIL conditioned medium following miR-7 induction. MiR-7 and S-TRAIL combination resulted in a robust reduction in the viability of TRAIL-unresponsive GBM cells compared with controls (Supplementary Figure S6B ; P < 0.05 compared with Figure S6C) . Similar reduction in cell viability was obtained when LN229-FmC-Tr-miR-7 GBM cells were co-cultured with MSC-S-TRAIL along with miR-7 induction ( Fig. 3D ; P < 0.01 compared with MSC-GFP). In vivo, mice bearing established intracranial LN229-FmC-Tr-miR-7 were administered doxycycline in drinking water and the following day (day 1) intratumorally implanted with MSC-S-TRAIL or MSC-GFP. The combination of miR-7 expression in tumor cells and MSC-S-TRAIL resulted in a significant decrease in tumor burden compared with the other groups (both days 4 and 7) (Fig. 3E) . These data reveal that the combination of forced expression of miR-7 and on-site delivery of S-TRAIL has potent therapeutic effects in TRAIL-unresponsive GBM cells in vivo.
MSC-GFP), which was associated with induction of apoptosis (Supplementary
AAV-Delivered miR-7 Attenuates GBM Growth Derived from Primary Patient-Derived GSCs
To test the efficacy of direct delivery of miR-7 to GBMs, we created an AAV bearing miR-7 and GFP (AGM7) (Fig.   4A ) and tested its efficacy in mice bearing intracranial tumors generated from a patient-derived primary GSC line engineered to express Fluc-mCherry, GBM4-FmC (Supplementary Figure S7) . A single dose of AGM7 (1 × 10 6 plaque forming units) injected intratumorally resulted in reduction in tumor volumes and significantly halted the progression of intracranial GBM4 tumors (P < 0.05 compared with controls) (Fig. 4B) . Histopathological analysis on serial brain sections from mice injected with AGM7 revealed infection of GBM cells, demonstrating the efficiency of AAV-mediated miR-7 delivery to the tumor cells in the brain on day 5 (Fig. 4C) . Further analysis at higher magnifications revealed a progressive reduction of viable mCherry+ tumor cells and sustained expression of GFP (miR-7) over time after AGM7 injection (Fig. 4D) . H&E staining analysis on serial brain sections also showed a reduction in tumor cell density post AGM7 injection compared with control AGFP (Fig. 4E) . These data reveal that AAV-delivered miR-7 results in suppression of intracranial GBM tumor cell growth in vivo. 
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Combination of AAV miR-7 Delivery and MSC-S-TRAIL Prolongs Survival of Mice Bearing GBM Xenografts Derived from Resistant Patient GSCs
In an effort to establish our mechanism based on miR-7 and S-TRAIL combination strategy for resistant tumors as a new therapeutic application, we tested the efficacy of the combination of AAV-miR-7 and MSC-S-TRAIL in mouse GBM models generated from patient-derived TRAILresistant GSCs. In vitro, a significant reduction in GBM4-FmC viability was seen upon combination treatment with AGM7 and S-TRAIL, which was reversed upon addition of pan-caspase inhibitor (Z-VAD-FMK), thereby confirming that the apoptotic cascade is involved in mediating the effect of the combination therapy (Fig. 5A, B) . Similar significant changes in GBM4-FmC viability were seen upon combination treatment of AGM7 and MSC-TRAIL in GBM4-FmC/MSC co-culture settings (Fig. 5C ). In vivo, mice bearing intracranial GBM4-FmC tumors were intratumorally injected with AGM7 or control AAV 72 h prior to intratumoral injection of MSC-TRAIL or MSC-GFP. Mice treated with the combination of AGM7 and MSC-S-TRAIL showed a significant reduction in tumor burden (P < 0.01 compared with tumor control and P < 0.05 compared with AGM7 + MSC-GFP; day 26) (Fig. 5D) . Immunofluorescence and H&E analysis on brain sections obtained from mice harvested at specified time points revealed upregulation of DR5 (Fig. 5E ) and subsequent loss of viable tumor cells (Fig.  5F ) post AGM7 + MSC-S-TRAIL treatment. Furthermore, the combined AGM7 and MSC-S-TRAIL therapy resulted in a significant increase in survival compared with controls, with 60% of the treated mice surviving long-term (Fig. 5G) (P < 0.01 compared with tumor control; and P < 0.05 compared with AGM7 + MSC-GFP). These data reveal that the combination of AAV-delivered miR-7 and MSC-S-TRAIL results in killing of patient-derived TRAIL-resistant GSCs in vivo and a prolonged survival of mice bearing intracranial resistant tumors.
Discussion
In this study, we investigated the role of miR-7 in facilitating TRAIL-induced apoptosis in GBM in vitro and in vivo. We show that expression of miR-7 results in the upregulation of DR5 and primes resistant GBM cells to TRAIL-mediated apoptotic cell death. In vivo, a single administration of AAV-miR-7 significantly decreases tumor volumes and when combined with stem cell-delivered TRAIL impairs tumor progression and significantly prolongs survival of mice bearing patient-derived GBM.
MiRNAs are emerging as key regulators of multiple pathways involved in development, differentiation, proliferation, and apoptosis and may become the next targeted therapeutics in GBM. The advantage of miRNA delivery as a cancer therapy is that a single microRNA can affect many pathways simultaneously to achieve clinical benefit. 23 Previously published studies reported that miR-7 is downregulated in GBM compared with surrounding normal brain, and miR-7 directly inhibits EGFR and suppresses Akt pathway activation, which are frequently upregulated in GBMs. 4 In the current study, we showed that miR-7 is downregulated in GBM cells compared with normal cells and that restoring miR-7 in these cells decreases GBM cell growth in both established and primary patient-derived GBM cells. TRAIL is known to selectively target tumor cells via DR4/5 while remaining harmless to most normal cells, and low expression of DR4/5 contributes to the resistance of tumor cells to TRAIL. 24 In addition, it is reported that constitutively active Akt regulates TRAIL resistance and downregulation of Akt makes TRAIL-resistant tumor cells sensitive to TRAIL in other types of cancer. [25] [26] [27] Therefore, upregulation of DR5 might be an effective strategy to overcome TRAIL resistance. Our studies show that miR-7 has a role in cell death pathway by upregulating DR5 expression in GBM cells and thereby opening up a therapeutic avenue by combination with S-TRAIL. Taken together, miR-7 regulates expression of EGFR and DR5 and downregulates Akt activity, and these diverse mechanisms of miR-7 underlie the sensitization of GBM to TRAIL-mediated apoptosis. Although the exact mechanism underlying the miR-7 mediated DR5 upregulation remains unclear, we show miR-7-induced increase in DR5 levels is key to priming resistant GBM cells to TRAIL. This might also contribute to activation of apoptosis via additional mechanisms such as NFkB. 28, 29 Previous studies have shown that NFkB p65 transcription factor plays a vital role in upregulation of DR5 via histone deacetylase 1. 30 Additionally, recently reported studies suggest that miR-7 is a strong activator of NFkB. 31 Our data on miR-7 activation of the NFkB p65 transcription factor provides insights into the role of NFkB p65 in miR-7 mediated priming of tumor cells to TRAIL-mediated apoptosis. Based on various reports suggesting the Akt-dependent regulation of NFkB transcription factor and the NFkB-mediated upregulation of DR5, 30, 32 we consider that NFkB is a key mediator to the proposed crosstalk between miR-mediated cell proliferation and TRAIL-mediated cell death pathway (Supplementary Figure S5) . However, an in-depth investigation to understand the critical role played by NFkB in linking the cell proliferation with cell death pathways is warranted to strengthen our findings.
The major impediments to the efficient delivery of many therapeutic molecules to the brain are the BBB 9 and vascular dysfunction in the tumor, 33 which prevent 
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systemically delivered drugs from reaching brain tumor cells. Although nanoparticles have been modified to enable encapsulation of miRNAs for tumor-specific delivery in numerous cancers, [34] [35] [36] [37] [38] their transport across the BBB and content release within the tumor cell are still major hindrances in utilizing them in CNS pathologies. We used an AAV-based vector system, as it is an attractive platform for regulatory RNA delivery. [39] [40] [41] When delivered by AAV, miRNAs are continually transcribed, allowing sustained high-level expression in target tissues. 40 In addition, the general safety of AAV has been well documented, with clinical trials using this platform already under way. [42] [43] [44] In our studies, we show that miR-7 can be effectively delivered on site to the GBM tumor environment using AAV vectors. This efficient delivery of miR-7 by AAVs presents a promising approach for delivering small RNAs, including miR in the brain.
The short half-life and the off-target toxicity of systemically delivered TRAIL pose a challenge in translating TRAIL cancer therapy into the clinics. 14 To address these limitations, we have previously established that stem cell-delivered TRAIL is very effective in GBM eradication due to its on-site delivery and long-term expression compared with systemically administered purified TRAIL. [15] [16] [17] However, many tumor lines, including some established and patient-derived tumor lines, have varying sensitivity to TRAIL-induced apoptosis, with about half of tumor lines being resistant to TRAIL. 21, 45 Therefore, sensitization of resistant GBM cells to TRAIL-mediated apoptosis is a valuable strategy that could lead to new treatment options for GBM. The induction of apoptosis by TRAIL is essentially dependent on the expression of specific cell surface TRAIL receptors and on the activation of caspases, 46 thus the regulation of the expression levels of those molecules is of fundamental importance. Our in vivo studies reveal that combination of AAV-mediated delivery of miR-7 and stem cell-delivered TRAIL resulted in marked attenuation of intracranial tumor growth and survival prolongation in mice bearing TRAIL-resistant GBM. Although established GBM lines are the most commonly used models in vitro and in vivo, they fail to recapitulate the clinical properties of tumors and are not a representative GBM model. Recent studies have focused on primary GBM lines and indicated a role for tumor-initiating cells in these lines. 18, 47 In an effort to understand the effect of miR-7 and stem cell-delivered TRAIL, we used GBM4, 18,47 a CD133+ primary GSC line that is unresponsive to S-TRAIL monotherapy. Our results revealed that the combination of miR-7 and S-TRAIL efficiently eliminated GBM4 cells in culture, and a robust reduction in tumor burden associated with an increase in survival was observed with a combination of AAV-delivered miR-7 and MSC-S-TRAIL. This therapeutic strategy presents a promising combinational approach to target heterogeneous tumors in the brain, which are otherwise unresponsive to DR ligands such as TRAIL.
In conclusion, our findings shed light on the unique role of miR-7 in priming resistant GBM cells to DR-ligand mediated apoptosis and serve as a foundation for developing therapies combining microRNA delivery and stem celldelivered pro-apoptotic agents for GBM.
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